Status:
COMPLETED
A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Tumors
Eligibility:
All Genders
20-75 years
Phase:
PHASE1
Brief Summary
The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral suberoylanilide hydroxami...
Eligibility Criteria
Inclusion
- Participants with histologically or cytologically diagnosed solid tumor; no standard therapy available or participant has failed to respond to standard therapy
Exclusion
- Participants with history of immunotherapy, radiotherapy, surgery, or chemotherapy during the previous 4 weeks; previous treatment is 5 or more chemotherapeutic regimens.
- Any uncontrolled concomitant illness
- Are pregnant or breast-feeding
- Serious drug or food allergy
Key Trial Info
Start Date :
June 10 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 21 2009
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00127127
Start Date
June 10 2005
End Date
August 21 2009
Last Update
September 13 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.